Abstract
The collection of fecal material and developments in sequencing technologies have enabled cost-efficient, standardized, and non-invasive gut microbiome profiling. As a result, microbiome composition data from several large cohorts have been cross-sectionally linked to various lifestyle factors and diseases.1–5 In spite of these advances, prospective associations between microbiome composition and health have remained uncharacterized due to the lack of sufficiently large and representative population cohorts with comprehensive follow-up data.6–8 Here, we analyse the long-term association between gut microbiome variation and mortality in a large, well-phenotyped, and representative population cohort (n = 7211, FINRISK 2002; Finland).9 We report specific taxonomic and functional signatures related to the Enterobacteriaceae family in the human gut microbiome that predict mortality during a 15-year follow-up. These associations can be observed both in the Eastern and Western Finns who have differing genetic backgrounds, lifestyles, and mortality rates.10,11 Our results supplement previously reported cross-sectional associations,1–4,12 and help to establish a methodological and conceptual basis for examining long-term associations between human gut microbiome composition, incident outcomes, and general health status. These findings could serve as a solid framework for microbiome profiling in clinical risk prediction, paving the way towards clinical applications of human microbiome sequencing aimed at prediction, prevention, and treatment of disease.
Competing Interest Statement
Veikko Salomaa has consulted for Novo Nordisk and Sanofi and received honoraria from these companies. He also has ongoing research collaboration with Bayer AG, all unrelated to this study.
Funding Statement
This research was supported in part by grants from the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, the Paavo Nurmi Foundation, the Urmas Pekkala Foundation, the Finnish Medical Foundation, the Academy of Finland (295741, 307127 to L.L.; 321351 to T.N.), UTUGS graduate school (to V.L.), and the National Institutes of Health (R01ES027595 to M.J., K01DK116917 to J.D.W., R01HL134168, R01HL131532, R01HL143227, and R01HL142983 to S.C.). Additional support was provided by Illumina, Inc. and Janssen Pharmaceutica through their sponsorship of the Center for Microbiome Innovation at UCSD.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the FINRISK Data Access Committee based on reasonable request [contact details available from T.N.]. The data are not publicly available due to them containing information that could compromise research participant privacy/consent.
